Klin Farmakol Farm. 2017;31(4):25-28 | DOI: 10.36290/far.2017.036

Unjustified discontinuation of statin preventive therapy – clinical consequences

Milan Kriška1, Jana Tisoňová1, Monika Laššánová1, Andrej Dukát2
1 Ústav farmakológie a klinickej farmakológie LF UK, Bratislava
2 V. interná klinika LF UK a UN, Bratislava

Statins – drugs belonging to the group of hypolipidemic drugs, are one of the most often prescribed drug groups. There is anincreasing number of trials clearly confirming significant decrease of morbidity and cardiovascular mortality while using them.Despite of existing papers reporting an increased risk perception, predominantly myopathy in elderly, great majority of publicationsconfirm statin benefits also in higher age levels and warn about consequencies of excluding them from preventive therapeuticschemes. In submitted paper we analyze the risk of withdrawal syndrome and point at the options of „statin restart“.

Keywords: prevention of cardiovascular morbidity, withdrawal syndrome, treatment restart

Received: July 18, 2017; Accepted: September 5, 2017; Published: January 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kriška M, Tisoňová J, Laššánová M, Dukát A. Unjustified discontinuation of statin preventive therapy – clinical consequences. Klin Farmakol Farm. 2017;31(4):25-28. doi: 10.36290/far.2017.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Krumholz HM. Statins evidence: When answers also raise questions Brit Med J 2016; DOI: 10,1136/bmj.i4963.Editorial Go to original source... Go to PubMed...
    2. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389. Go to original source...
    3. Ford J, Murray H, Packard CH Shepherd J, Macfarlane PW, Cobbe MS. For the West of Scotland Coronary Prevention Study Group N Engl J Med 2007; 357: 1477-1486. Go to original source... Go to PubMed...
    4. Dukát A, Kriška M. Zlyhanie farmakoterapie hypolipidemikami. In: Zlyhanie farmakoterapie-možnosti prevencie. SAP Bratislava 2015: s. 218-233.
    5. Stroes ES, Thompson PD, Corsini A a spol 2015, Statin assotiated Muscle Symptoms impact on statin therapy-European Atherosclerosis Society Concensus Panel Statement on Asssesmentnt, Aethiology and Management Eur Heart j 2015; 36: 1012-1102. Go to original source...
    6. USPST Statin recommendations for CVDprevention, published in JAMA 2016.
    7. Collins R, Emberson J, Armitage J, Baigent C, Ridker P, Yusuf S, a kol. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2534-2561. Go to original source... Go to PubMed...
    8. Miller EP, Martin SS. Interpretation of the evidence for the efficacy and safety of statin therapy. Atheroscler Res 2016; 18: 20. Go to original source... Go to PubMed...
    9. Vera MA, Bhole V, Burns LC, a kol. Impact of statin adherence on cardiovascular disease and mortality outcomes. Br J Pharmacol 2014; 78: 684-698. Go to original source... Go to PubMed...
    10. Ho PM, Magid DJ, Shetterly SM, a kol. Medication Nonadherence Is Associated With a Broad Range of Adverse Outcomes in Patients With Coronary Artery Disease. Am Heart J. 2008; 155(4): 772-779. Go to original source... Go to PubMed...
    11. Strojil J, Urbánek K, Sobolová L. Compliance pri léčbě statíny. Klin Farmacol Farm 2005; 19: 146-148.
    12. Dukát A. Vedľajšie účinky liečby statínmi, ich intolerancia a monosti prevencie. Lekárnické listy. 2016; 18(6): 26-28.
    13. Laššanová M, Tisoňová J, Kriška M. Môžu byť problémy pri liečbe statínmi? Klin Farmakol Farm 2005; 19: 160-164.
    14. Clark R, Gillett JR, Norrell A. Considerations for Safe Use of Statins: Liver Enzyms Abnormalities and Muscle Toxicity. Am Fam Physician 2011; 83(6): 711-716. Go to PubMed...
    15. Dukát A, Kriška M. Vedľajšie nežiaduce účinky liečby statínmi: statíny a manifestácia novozisteného diabetes mellitus 2. typu. Diabetes a obezita, 2013; 13(25): 9-16. ISSN 1335-8383.
    16. Culver AL, Ockene IS, Balasubramanian R, a kol. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. 1. Arch Intern Med. 2012 Jan 23; 172(2): 144-152. doi: 10.1001/archinternmed.2011.625. Go to original source... Go to PubMed...
    17. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.http://www.nejm.org/toc/nejm/353/5/ Go to original source... Go to PubMed...
    18. Thomas M, Mann J. Increased thrombotic vascular events after change of statin, The Lancet, 1998; 235: s 1830-1831. Go to original source... Go to PubMed...
    19. Heeschen Ch, a kol. Witdrawal of statins increases event rates in patients with acute coronary syndromes. Cirulation, 2002: 105: 1446-1452. Go to original source... Go to PubMed...
    20. Zhandg H, Plutzky J, Skentzos S, a spol. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013; 158: 526-534. Go to original source... Go to PubMed...
    21. Blanco M, Nombela F, Rodriges, Castelanos M, a kol. Statin treatment withdrawal in ischemic stroke. Neurology, 2007; 69(9): 904-910. Go to original source... Go to PubMed...
    22. Pineda A, Cebedu LX. Statin rebound or withdrawal syndrome: does it exist? Current Atherosclerosis Reports, February 2011; 13(1): 23-30. Go to original source... Go to PubMed...
    23. Vinogradova Y, Coupland C, Brindle P, a kol. Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database. BMJ 2016; 353: i3305 http://dx.doi.org/10.1136/bmj.i3305 Go to original source... Go to PubMed...
    24. Wei L, Wang J, Thompson P, a spol. Adherence to statin treatment and readmission of patients after myocardial infarction: a six followup study. Heart 2002; 88: 229-233. Go to original source... Go to PubMed...
    25. Akincigil A, Bowblis JR, Levin C, a spol. Long term adherence to evidence based secondary prevention therapies after acute myocardial infarction. J. Gen. Intern. Med. 2008; 23: 115-121. Go to original source... Go to PubMed...
    26. Gajdošík J, Bruckerová D, Kriška M, Zelina M. Ako je to s vnímaním možného rizika liekov u pacientov užívajúcich nesteroidové antiflogistiká-analgetiká. Klin Farmakol Farm 2013; 27: 57-60.
    27. Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J, 2016; 37: 908-916. Go to original source... Go to PubMed...
    28. Gupta A, Thompson D, Whitehouse A, a kol. Adverse events associated with unblinded, but not with blinded, statin therapy in theAnglo-Scandinavian Cardiac Outcomes Trial-Lipid-LoweringArm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017; May 2. pii: S0140-6736(17)31075-9. doi: 10.1016/S0140-6736(17)31075-9.[Epubaheadofprint] Go to original source... Go to PubMed...
    29. Laššán Š, Laššánová M, Kriška M, Kristová V, Dukát A. Očakávané prínosy vo vzťahu k riziku pri liečbe statínmi. Cardiol 2003; 12(2): 85-94.
    30. Kriška M, Gajdošík J, Dukát A, Bernadič M. Prevencia zlyhania farmakoterapie v bežnej klinickej praxi. Med. Monitor 2016; 3: 2-4.
    31. Gajdošík J, Brukkerová D, Kriška M, a kol. Poznáme dostatočne ochotu pacienta dodržiavať pokyny lekára? Prakt Lék 2007; 87: 103-107.
    32. Eisenberg T, Wells MT. Statin, Cholesterol, women and primary prevention: Evidence based Medicine or wishfull thinks. Future Cardiol 2009; 5: 1-4. Go to original source... Go to PubMed...
    33. Kriška M, Dukát A, Gajdošík J, Bernadič M. Zlyhanie farmakoterapie - možnosti prevencie SAP 2015: S 320.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.